Group 1 - The stock of EnGeneIC Limited (09606) opened over 4% higher and is currently up 4.63%, trading at 380 HKD with a transaction volume of 7.506 million HKD [1] - EnGeneIC Limited announced that starting from September 8, 2025, its shares will be included in the Hang Seng Composite Index and added to the eligible securities list for the Shanghai-Hong Kong Stock Connect [1] - The inclusion in the Hang Seng Composite Index and the Shanghai-Hong Kong Stock Connect is seen as a recognition of the company's performance and value, potentially expanding its investor base and increasing trading liquidity [1] Group 2 - On September 5, EnGeneIC Limited reported that an independent data monitoring committee (IDMC) evaluated that the DB-1303/BNT323 treatment achieved the primary endpoint of progression-free survival (PFS) in a Phase III clinical trial for HER2-positive unresectable or metastatic breast cancer patients previously treated with trastuzumab and taxanes [1] - The company plans to communicate with the National Medical Products Administration's Drug Evaluation Center regarding the submission of a Biologics License Application (BLA) for DB-1303/BNT323 [2] - DB-1303/BNT323 is a clinical-stage HER2ADCD candidate drug currently undergoing two ongoing registration clinical trials and another potential global registration study [2]
映恩生物-B高开逾4% 获纳入恒生综合指数成份股 乳腺癌新药III期临床达主要终点